AbbVie Inc. CDR (ABBV)
TSX
38.50
+0.76 (+2.01%)
Closed
Oct 9, 2026
Day's Range
38.0738.51
52 wk Range
26.8938.51
Financial Statements - ABBV - AbbVie Inc. CDR
Revenue
61.16B▼ 20.6%
Net Income
4.23B▼ 27.8%Net Margin 6.9%
EBITDA
22.70B▼ 6.1%
Free Cash Flow
17.81B▼ 26.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 61.16B | 77B |
| Cost of Goods | 18.20B | 23.10B |
| Gross Profit | 42.95B | 53.89B |
 Operating Expense | - | - |
| Operating Income | 20.09B | 16.25B |
| Non-Operating Interest | - | - |
| Other Income Expense | -10.86B | -8.22B |
| Pre Tax Income | 6.59B | 5.07B |
| Income Tax | 2.36B | -779.17M |
| Net Income | 4.23B | 5.85B |
| EPS Basic | 0.252986 | 0.256479 |
| EPS Diluted | 0.249764 | 0.252939 |
| Basic Shares Outstanding | 16.70B | 22.80B |
| Diluted Shares Outstanding | 16.70B | 22.80B |
| Ebit | 9.49B | 8.91B |
| Ebitda | 22.70B | 24.17B |
| Net Income Continuous Operations | 4.23B | 5.85B |
| Minority Interests | -7M | -8M |
| Preferred Stock Dividends | 40M | 54.67M |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
